Icure Pharmaceutical Incorporation - Asset Resilience Ratio
Icure Pharmaceutical Incorporation (175250) has an Asset Resilience Ratio of 5.45% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 175250 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Icure Pharmaceutical Incorporation's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 175250 asset base.
Liquid Assets Composition Over Time
This chart breaks down Icure Pharmaceutical Incorporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 175250 long-term investments to assets to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩4.49 Billion | 3.63% |
| Short-term Investments | ₩2.25 Billion | 1.82% |
| Total Liquid Assets | ₩6.75 Billion | 5.45% |
Asset Resilience Insights
- Limited Liquidity: Icure Pharmaceutical Incorporation maintains only 5.45% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Icure Pharmaceutical Incorporation Industry Peers by Asset Resilience Ratio
Compare Icure Pharmaceutical Incorporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Kamada
TA:KMDA |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723 |
Drug Manufacturers - Specialty & Generic | 1.01% |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL |
Drug Manufacturers - Specialty & Generic | 5.90% |
Annual Asset Resilience Ratio for Icure Pharmaceutical Incorporation (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Icure Pharmaceutical Incorporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 16.88% | ₩22.44 Billion ≈ $15.20 Million |
₩132.88 Billion ≈ $90.05 Million |
+11.73pp |
| 2023-12-31 | 5.15% | ₩8.56 Billion ≈ $5.80 Million |
₩166.14 Billion ≈ $112.59 Million |
-18.85pp |
| 2022-12-31 | 24.00% | ₩53.79 Billion ≈ $36.45 Million |
₩224.12 Billion ≈ $151.88 Million |
+12.67pp |
| 2021-12-31 | 11.33% | ₩24.42 Billion ≈ $16.55 Million |
₩215.45 Billion ≈ $146.01 Million |
+4.30pp |
| 2020-12-31 | 7.03% | ₩13.72 Billion ≈ $9.30 Million |
₩195.15 Billion ≈ $132.25 Million |
-1.77pp |
| 2019-12-31 | 8.80% | ₩18.99 Billion ≈ $12.87 Million |
₩215.80 Billion ≈ $146.24 Million |
-19.97pp |
| 2018-12-31 | 28.77% | ₩34.81 Billion ≈ $23.59 Million |
₩121.00 Billion ≈ $82.00 Million |
+11.05pp |
| 2017-12-31 | 17.72% | ₩9.55 Billion ≈ $6.47 Million |
₩53.90 Billion ≈ $36.53 Million |
+14.35pp |
| 2016-12-31 | 3.37% | ₩1.06 Billion ≈ $720.17K |
₩31.53 Billion ≈ $21.36 Million |
-- |
About Icure Pharmaceutical Incorporation
Icure Pharmaceutical Incorporation, a biopharmaceutical company, researches, develops, and sells pharmaceutical and cosmetic products in South Korea. The company offers functional, nature-derived, derma, and customized cosmetics products. It also offers eye gel, hydro nude gel, lip gel mask, and functional patch products; and sheet, mud, foil, and melting masks. In addition, the company provides … Read more